SCHEMBL2605696

SCHEMBL2605696

CCNC(=O)c1cccc(-c2ccccc2)c1F

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.56
CHRNB2 P17787 3/20 0.51
CHRNA4 P43681 3/20 0.51
CHRNB4 P30926 2/20 0.51
CHRNA3 P32297 2/20 0.51
SUCNR1 Q9BXA5 1/20 0.48
KMT2A Q03164 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HTT P42858 5/20 0.46
BRD4 O60885 2/20 0.45
LMNA P02545 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CXCR2 P25025 1/20 0.44
PIN1 Q13526 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7217604 0.85 CHRNB2 (0.68) CHRNB2CHRNA4CHRNB4CHRNA3KMT2A
SCHEMBL30147654 0.83 KAT6A (0.59) KAT6ACHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL15074688 0.83 KAT6A (0.59) KAT6ACHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL30739831 0.79 CES2 (0.55) KAT6AKMT2AL3MBTL1HTTBRD4
SCHEMBL10172579 0.79 KAT6A (0.56) KAT6ACHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL13927497 0.79 KAT6A (0.56) KAT6ACHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL24246862 0.78 KAT6A (0.56) KAT6AKMT2AL3MBTL1HTTBRD4
SCHEMBL25078393 0.78 HTT (0.51) KAT6AKMT2AL3MBTL1HTTBRD4
SCHEMBL121804 0.77 HNF4A (0.63) KAT6ACHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL13824012 0.76 SLC6A3 (0.64) KAT6AKMT2AHTTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907091-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-8389541-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2013-03-05 US disclosed
US-20120108628-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY Mirati Therapeutics, Inc. 2012-05-03 US disclosed
US-20120095234-A1 PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS Mirati Therapeutics, Inc. 2012-04-19 US disclosed
US-20090286984-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors Mirati Therapeutics, Inc. 2009-11-19 US disclosed
US-20090264440-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY Mirati Therapeutics, Inc. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095234-A1 PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS MAP3K19, MAP3K9, MAP4K2 KAT6A 2134/4885CHRNB2 3838/4885CHRNA4 3598/4885
US-20090286984-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors MAP3K19, MAP3K9, MAP4K2 KAT6A 2134/4885CHRNB2 3838/4885CHRNA4 3598/4885
US-20090264440-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET KAT6A 3788/4885CHRNB2 4800/4885CHRNA4 4873/4885
US-20120108628-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET KAT6A 3788/4885CHRNB2 4800/4885CHRNA4 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.